Tina Marriott - Dec 16, 2021 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
President and COO
Signature
/s/ Jonathan Golightly, attorney-in-fact
Stock symbol
RXRX
Transactions as of
Dec 16, 2021
Transactions value $
-$46,848
Form type
4
Date filed
12/20/2021, 05:00 PM
Previous filing
Nov 22, 2021
Next filing
Feb 8, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Sale -$21K -1.16K -2.32% $18.09 48.8K Dec 16, 2021 Direct F1, F2
transaction RXRX Class A Common Stock Sale -$19.9K -1.04K -2.13% $19.17 47.8K Dec 16, 2021 Direct F1, F3
transaction RXRX Class A Common Stock Sale -$5.93K -300 -0.63% $19.78 47.5K Dec 16, 2021 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sales are pursuant to a 10b5-1 trading plan established by the Reporting Person.
F2 The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $17.63 to $18.53 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
F3 The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $18.69 to $19.55 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
F4 The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $19.69 to $19.93 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.